22.04.2026 Oral Phenylephrine Phase-Out Puts OTC Brands Under Review Oral Phenylephrine Phase-Out debate grows as Sahpra weighs evidence, industry warns on access, and pharmacists call for a gradual transition. This article is for Health Matters subscribers Subscribers read every article in full, receive the daily briefing and have access to the complete archive. SubscribeLog in Cold And Flu, Evidence-Based Policy, FDA, Market Access, Medicines Quality And Efficacy, OTC Medicines, pharmacy, Regulation, Respiratory Health, South Africa